Welcome to our dedicated page for Alumis news (Ticker: ALMS), a resource for investors and traders seeking the latest updates and insights on Alumis stock.
Alumis Inc. (Nasdaq: ALMS) is a late-stage biopharma and clinical-stage biopharmaceutical company developing next-generation targeted therapies for immune-mediated diseases. The Alumis news feed on Stock Titan aggregates company press releases and market-moving updates so readers can review the latest disclosures directly from the issuer.
In its news releases, Alumis highlights progress across a pipeline centered on precision immunology. Key updates include clinical data and trial milestones for envudeucitinib (envu, formerly ESK-001), a next-generation, highly selective oral TYK2 inhibitor being studied in the Phase 3 ONWARD program for moderate-to-severe plaque psoriasis and the Phase 2b LUMUS trial in systemic lupus erythematosus. The company has reported positive topline Phase 3 results in plaque psoriasis and completion of enrollment in the LUMUS SLE study, along with prior Phase 2 data publications.
News items also cover advancement of A‑005, a potentially first‑in‑class fully CNS‑penetrant oral TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases, and lonigutamab, a subcutaneous anti‑IGF‑1R therapy for thyroid eye disease that has received Fast Track Designation from the U.S. Food and Drug Administration, as described by Alumis. Corporate and financial announcements include quarterly financial results, guidance on cash runway, collaboration revenue from Kaken Pharmaceutical, participation in healthcare investor conferences, and details of the company’s merger with ACELYRIN, Inc.
Investors following ALMS news can use this page to review updates on public offerings of common stock conducted under Alumis’ shelf registration statement, regulatory and clinical milestones for its late-stage programs, and other operational developments described in its press releases. Bookmark this news feed to monitor how Alumis communicates clinical progress, capital markets activity and strategic initiatives related to its immune-mediated disease pipeline.
Alumis Inc. (Nasdaq: ALMS) has initiated the ONWARD Phase 3 clinical program for ESK-001, an oral TYK2 inhibitor, in moderate-to-severe plaque psoriasis. The program includes two identical 24-week global trials (ONWARD1 and ONWARD2) and a long-term extension trial (ONWARD3). The co-primary endpoints are PASI 75 and sPGA 0/1 score at 24 weeks, which will serve as the basis for U.S. regulatory submission.
The pivotal program is supported by positive Phase 2 STRIDE clinical data and an ongoing open-label extension study. Topline data is anticipated in 2026. ESK-001 aims to address the unmet need for an oral treatment that delivers high efficacy without compromising safety in psoriasis patients. The company is also evaluating ESK-001 in a Phase 2b trial for systemic lupus erythematosus and exploring its potential in other autoimmune indications.
Alumis, a clinical-stage biopharmaceutical company, has priced its initial public offering (IPO) at $16.00 per share for 13,125,000 shares. The company has also provided a 30-day option for underwriters to purchase an additional 1,968,750 shares. Trading on Nasdaq is set to begin on June 28, 2024, under the symbol 'ALMS', with the offering expected to close on July 1, 2024. Concurrently, Alumis will sell 2,500,000 shares in a private placement to AyurMaya Capital Management Fund at the same price.
The total expected gross proceeds from both the IPO and the private placement are projected to be $250 million, excluding underwriters' exercise options. The private placement is subject to a 180-day lock-up agreement and will close by July 22, 2024, contingent on the IPO's closure. Leading the IPO are Morgan Stanley, Leerink Partners, Cantor, and Guggenheim Securities.